Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
The upcoming earnings report for KVUE is scheduled for Wednesday, May 6th. Analysts expect a consensus EPS of 0.27.
Kenvue Inc. is currently trading at $17.67, marking a 0.8% increase from the previous close. The trading volume is $7.92 million, 24.89% above the average.
The latest quarterly earnings for KVUE were reported on Monday, February 16th, with a consensus EPS of 0.2227. Further details on revenue and profit margin are awaited.
KVUE offers a forward dividend yield of 4.7%, with a dividend per share MRQ of 20.75 cents. The year-over-year increase in dividend per share is notable at 1.8519 cents.
Key financial ratios for KVUE include a gross profit margin of 56.53%, operating profit margin of 21.83%, and a return on equity of 3.07. The price-earnings ratio stands at 24.95, indicating investor sentiment.
Stay tuned for further updates on KVUE's performance as the market continues to react to earnings expectations and financial health indicators.